• Dispersa

  Participated · Seed · Mar 2026

  Founded in 2019, Canada-based Dispersa has developed BioEterna®, a synthetic-biology and precision-fermentation platform that feeds waste oils and sugars to microbes, producing PuraSurf®, the world’s first 100% waste-derived biosurfactant. The ingredient can slot into cleaners, detergents, shampoos, cosmetics and other formulations traditionally reliant on fossil or palm inputs. With facilities in Laval, Québec and biomanufacturing partners in Nova Scotia, the company is nearing 100-tonnes-per-year production capacity and is preparing to fulfill commercial orders across North America. Dispersa’s circular model simultaneously diverts food waste from landfills and lowers the carbon and biodiversity impacts tied to conventional surfactants. The startup has raised more than $13 million CAD to date, enabling its transition from lab proof-of-concept to commercial-scale manufacturing. Seed funding is being deployed to expand production, accelerate customer integrations and advance additional waste-to-chemical product lines.

• Arkea Bio

  Participated · Series A · May 2024

  ArkeaBio is developing a safe, user-friendly, and cost-conscious vaccine designed to reduce methane emissions from ruminant livestock and to integrate with existing global agribusiness practices. The company positions the vaccine as a scalable, low-cost tool to address agricultural methane, which the release cites as generating the equivalent of 3 billion tonnes of CO2 annually (about 6% of annual GHG emissions). ArkeaBio says its R&D results have attracted investor attention and that the vaccine is designed for rapid, on-farm implementation. The Series A proceeds will fund expansion of research and development, large-scale field trials, and engagement along the supply chain to support deployment. The company emphasizes collaborative work with industry partners, regulators, and environmental organizations to bring the product to market. Financially, ArkeaBio announced the close of a $26.5 million Series A financing to accelerate development and commercialization. ArkeaBio is a Boston, MI-based company developing an innovative vaccine to reduce methane emissions from ruminant animals, including cattle, sheep, and goats. Led by CEO Colin South, the company expects ruminant vaccinations to be a scalable and cost-effective solution to rapidly decarbonize global meat and dairy production. Its technology is intended to be integrated into proven delivery systems and existing farming practices to reduce methane emissions across multiple ruminant species, geographies, and agronomic systems. ArkeaBio intends to use newly raised funds to accelerate its research program. The company has stated it will position itself as a leader in the global effort to decarbonize the agricultural sector. No operating metrics were disclosed in the article.

No current team members are available.